Kyzatrex: Oral Testosterone Restores Hormonal Homeostasis in Hypogonadal U.S. Men
Reading Time: 2 minutes Introduction Hypogonadism, characterized by deficient testosterone production, affects an estimated 2-6 million American men, with prevalence rising sharply after age 40 due to age-related androgen decline, obesity, and comorbidities like type 2 diabetes. This endocrine imbalance manifests as fatigue, reduced libido, erectile dysfunction, diminished muscle mass, and mood disturbances, profoundly impacting quality of life. Traditional testosterone replacement therapy (TRT) options, such as intramuscular injections and transdermal gels, often face adherence challenges due to pain, skin irritation, or daily application requirements. Enter Kyzatrex, an FDA-approved oral testosterone undecanoate capsule (200 mg), offering a convenient, once- or twice-daily regimen that bypasses hepatic...


